Recently, third-generation cryosurgery has been widely introduced into clinical practice using argon-driven, ultrathin 17-gauge cryoprobes in accordance with the Joule-Thompson principle.[1-3] Contemporary cryosurgery includes these technologic advances along with the routine utilization of ultrathin needles incorporating a thermal monitoring system (TMS) for temperature surveillance, transrectal ultrasound (TRUS) imaging, and a urethral warming catheter to minimize morbidity associated with the procedure.[4-7] These developments allow for accurate targeting of even small solitary lesions that can aid in focal cryoablation of prostate cancer.
This review highlights trends in cryotechnique development, basic cryobiology, and primary whole-gland cryoablation including a recent trend toward organ-sparing procedures such as hemiablation and focal targeted cryoablation.
Advances in Cryotechnology and Cryobiology
Refining Cryoneedles and Temperature Monitoring
Gowardhan et al recently presented experimental testing in an in vitro phantom prostate model and subsequent clinical study of 20 prostate cancer patients. These patients were treated with cryoablation using new developments in third-generation cryotechnology such as the IceRodTM (Oncura, Amersham, UK) 17-gauge cryoneedles with an advanced heat exchanger and the MultitempTM 1601 TMS (InvivoSense, Trondheim, Norway).
The IceRodTM probes demonstrated a better ability to freeze tissue reaching lower temperatures and forming iceballs with a maximum diameter > 6 cm after freezing at full power for 10 minutes. In other words, these probes can be used in prostates measuring > 3.5 cm in sagittal length, obviating the need for a “pull-back” technique sometimes required when using probes that generate smaller volumes of ice. TMS monitoring depicted real-time temperature gradients over either 4 or 8 temperature points arranged in linear gradients, suggesting that single-point temperature monitoring might not accurately depict the lowest critical temperatures reached during treatment when completely ablating tumor cells. These innovations may potentially improve cryosurgical technique and facilitate the procedure in a potentially safer, targeted, reproducible form, allowing beginners to learn the procedure more quickly and efficiently.
Baust et al presented an update of critical experimental and clinical issues regarding the successful clinical application of cryosurgical ablation for prostate cancer. These authors presented information on the molecular basis of tissue response to freezing, identifying apoptosis as a significant part of tumor destruction after cryoablation. This paper provides an excellent basic science foundation for translational research highlighting suggested improvements in the clinical implementation of this technique, such as optimization of the freeze cycle duration, optimization of target tissue temperature, and adjunctive combination of chemotherapy with cryotherapy.
1. Miller R, Cohen JK: Prostate cryosurgery, in Rukstalis DB, Katz AE (eds): Handbook of Urologic Cryoablation, pp 39-46. London, Informa UK Ltd, 2007.
2. Han KR, Belldegrun AS: Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 93:14-18, 2004.
3. Mouraviev V, Polascik TJ: Update on cryosurgery for prostate cancer in 2006. Cur Opin Urol 16:152-156, 2006.
4. Han KR, Cohen JK, Miller RJ, et al: Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. J Urol 170:1126-1130, 2003.
5. Prepelica KL, Okeke Z, Murphy A, et al: Cryosurgical ablation of the prostate: High risk patient outcomes. Cancer 103:1625-1630, 2005.
6. Baust JG, Gage AA, Klossner D, et al: Issues critical to the successful application of cryosurgical ablation of the prostate. Technol Cancer Res Treat 6:97-109, 2007.
7. Polascik TJ, Nosnik I, Mayes JM, et al: Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology 70:117-121, 2007.
8. Gowardhan B, Greene D: Cryotherapy for the prostate: An in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system. BJU Int 100:295-302, 2007.
9. Baust JG, Gage AA: The molecular basis of cryosurgery. BJU Int 95:1187-1191, 2005.
10. Clarke DM, Baust JM, Van Buskirk RG, et al: Addition of anticancer agents enhances freezing-induced prostate cancer cell death: Implications of mitochondrial involvement. Cryobiology 49:45-61, 2004.
11. Klossner DP, Robilotto AT, Clarke DM, et al: Cryosurgical technique: Assessment of the fundamental variables using human prostate cancer model systems. Cryobiology 55:189-199, 2007.
12. Gonder MJ: Cryosurgery in prostate carcinoma: Clinical evidence of immunostimulation of host versus tumor. Natl Cancer Inst Monogr 369, 1978.
13. Ablin R: An appreciation and realization of the concept of cryoimmunology, in Onik G, Rubinsky B, Watson G, et al (eds): Percutaneous Prostate Cryoablation, pp136-154. St. Louis, Quality Medical Publishing, 1995.
14. Mouraviev V, Prochorov G, Ablin R: The combined cytoreductive cryoablation and immunochemotherapy for advanced prostate cancer (abstract 116). Abstracts of the 5th World Congress on Advances in Oncology, Rhodes, Greece, October 15-18. Int J Mol Med 6(suppl 1):202, 2000.
15. Hayakawa K, Yamashita T, Suzuki K, et al: Comparative immunological studies in rats following cryosurgery and surgical excision of 3-methylcholanthrene-induced primary autochthonous tumors. Gann 73:462-469, 1982.
16. Hoffmann NE, Coad JE, Huot CS, et al: Investigation of the mechanism and the effect of cryoimmunology in the copenhagen rat. Cryobiology 42:59-68, 2001.
17. Udagawa M, Kudo-Saito C, Hasegawa G, et al: Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res 12:7465-7475, 2006.
18. Machlenkin A, Goldberger O, Tirosh B, et al: Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res 11:4955-4961, 2005.
19. Shelley M, Wilt T, Coles B, et al: Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 18:1-16, 2007.
20. Donnelly BJ, Saliken JC, Ernst DS, et al: Prospective trial of cryosurgical ablation of the prostate: Five-year results. Urology 60:645-649, 2002.
21. Bahn DK, Lee F, Badalament R, et al: Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60:3-11, 2002.
22. Wong WS, Chinn DO, Chinn M, et al: Cryosurgery as a treatment for prostate carcinoma: Results and complications. Cancer 79:963-974, 1997.
23. Jones J, Donnelly B, Pisters LL, et al: Primary prostate cryoablation: Results from 1198 patients tracked with the COLD registry (abstract 1773). AUA Annual Meeting Program Abstracts. J Urol 177(suppl):589, 2007.
24. Cresswell J, Asterling S, Chaudhary M, et al: Third-generation cryotherapy for prostate cancer in the UK: A prospective study of the early outcomes in primary and recurrent disease. BJU Int 97:969-974, 2006.
25. Mouraviev V, Nosnik I, Sun L, et al: Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: A single-institution experience. Urology 69:311-314, 2007.
26. Robinson JW, Donnelly BJ, Saliken JC, et al: Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 60:12-18, 2002.
27. Ball AJ, Gambill B, Fabrizio MD, et al: Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: A short-term evaluation of five approaches from a single institution. J Endourol 20:723-731, 2006.
28. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004.
29. Cheng L, Jones TD, Pan CX, et al: Anatomic distribution and pathologic characterization of small-volume prostate cancer (
30. Stamey TA, McNeal JE, Yemoto CM, et al: Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-1400, 1999.
31. Stamey TA, Donaldson AN, Yemoto CE, et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 160:2412-2417, 1998.
32. Noguchi M, Stamey TA, McNeal JE, et al: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers. J Urol 170:459-463, 2003.
33. Renshaw AA, Richie JP, Loughlin KR, et al: Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol 111:641-644, 1999.
34. Rukstalis DB, Goldknopf JL, Crowley EM, et al: Prostate cryoablation: A scientific rationale for future modifications. Urology 60:19-25, 2002.
35. Epstein JI, Carmichael MJ, Partin AW, et al: Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: Pathogenetic and clinical implications. J Urol 151:1587-1592, 1994.
36. Mouraviev V, Mayes JM, Sun L, et al: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110:906-910, 2007.
37. Bostwick DG, Shan A, Qian J, et al: Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 83:1995-2002, 1998.
38. Mouraviev V, Sun L, Madden JF, et al: Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology 70:1141-1145, 2007.
39. Ohori M, Eastham JA, Koh H, et al: Is focal therapy reasonable in patients with early stage prostate cancer (CaP)—an analysis of radical prostatectomy (RP) specimens (abstract 1574). J Urol 175(suppl):507, 2006.
40. Lambert EH, Bolte K, Masson P, et al: Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 69:1117-1120, 2007.
41. Bahn DK, Silverman P, Lee F Sr, et al: Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 20:688-692, 2006.
42. ASTRO: Consensus Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997.
43. Crawford ED, Barqawi A: Targeted focal therapy: A minimally invasive ablation technique for early prostate cancer. Oncology (Williston Park) 21:27-39 (incl discussion), 2007.
44. Ahmed HU, Pendse D, Illing R, et al: Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 4:632-642, 2007.
45. Eggener SE, Scardino PT, Carroll PR, et al: Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 178:2260-2267, 2007.
46. Jones JS: Focal or subtotal therapy for early stage prostate cancer. Curr Treat Options Oncol 8:165-172, 2007.
47. Barqawi AB, Crawford ED: The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J 13:313-317, 2007.
48. Onik G: Rationale for a "male lumpectomy," a prostate cancer targeted approach using cryoablation: Results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radiol 31: 98-106, 2008.
49. D´Amico AV: Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Williston Park) 15:1049-1059, 2001.
50. Cohen JK: Cryosurgery of the prostate: Techniques and indications. Rev Urol 6:S21-S26, 2004.
51. Roach MR, Hanks G, Thames HJ, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 15 965-974, 2006.